Bavarian Nordic Beefs Up Chikungunya Vaccine Race With Valneva With Encouraging Late-Stage Trial Data
Portfolio Pulse from Vandana Singh
Bavarian Nordic's phase 3 chikungunya virus vaccine trial has hit its primary endpoint in healthy adults aged 65 and above. The company acquired the vaccine candidate from Emergent BioSolutions for $380 million and is competing with Valneva's VLA1553 vaccine.
June 20, 2023 | 6:30 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Bavarian Nordic acquired the phase 3 chikungunya vaccine candidate from Emergent BioSolutions for $380 million.
Emergent BioSolutions has already sold the chikungunya vaccine candidate to Bavarian Nordic for $380 million, so the success of the trial may not have a direct short-term impact on EBS's stock price.
CONFIDENCE 90
IMPORTANCE 60
RELEVANCE 50
NEUTRAL IMPACT
Bavarian Nordic's chikungunya vaccine trial is competing with Valneva's VLA1553 vaccine.
Both Bavarian Nordic and Valneva are developing chikungunya vaccines, and the success of one may not necessarily impact the other's stock price in the short term, as both vaccines have shown promising results.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Bavarian Nordic's phase 3 chikungunya vaccine trial shows promising results, competing with Valneva's VLA1553.
Bavarian Nordic's phase 3 chikungunya vaccine trial has hit its primary endpoint, showing promising results. This could potentially lead to increased demand for the vaccine and boost the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100